Elanix Biotechnologies AG Company news
2023
2022
2021
2020
27.02.2020
Resignation and nomination in the supervisory board
2019
13.05.2019
Strafrechtliche massnahmen gegen den ehemaligen vorstand thomas j. svoboda und zwei mutmasslichen mitwissern sind erfolgt
18.04.2019
Elanix Biotechnologies AG: NOMINATION OF THE CHAIRMAN OF THE SUPERVISORY BOARD, THE VICE CHAIRMAN AND MEMBERS OF THE BOARD
14.02.2019
Elanix Biotechnologies AG: Resignation in Supervisory Board
14.02.2019
Elanix Biotechnologies AG: Criminal charges to be filed against former CEO Tomas J. Svoboda
11.02.2019
Elanix Biotechnologies AG annuls profit guidance and preliminary earnings for fy 2017
07.02.2019
Elanix Biotechnologie AG: Major Shareholder requests extraordinary general assembly to replace the Chairman of the Supervisory Board
2018
23.11.2018
Elanix Biotechnologies AG: Professor Laurent-Applegate, founder and Interim-CEO, announces sale of shares in Elanix Biotechnologies AG
12.11.2018
Elanix Biotechnologies AG: Revocation of the appointment of Mr. Tomas J. Svoboda (CEO) as member of the Executive Management Board (Vorstand)
09.11.2018
The Management Board of Elanix Biotechnologies AG will make corrections to its 2017 financial statements due to a fault detection by Deutsche Prüfstelle für Rechnungslegung with regard to the accounting of intangible assets in the 2015 consolidated financial statements.
24.07.2018
Elanix Biotechnologies AG resolves a capital increase of up to 10 percent equaling 2.1 Mio EUR with indirect subscription rights using the authorized capital
28.05.2018
Elanix Biotechnologies AG resolves a capital increase of up to 10 percent with the exclusion of subscription rights using the authorized capital
30.04.2018
Elanix Biotechnologies AG secures up to EUR 2.5 Million SEDA (Standby Equity Distribution Agreement) financing
20.02.2018
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
14.02.2018
Elanix Biotechnologies AG: Elanix Biotechnologies AG places a total of 300,019 shares from the current cash capital increase and signs a Term Sheet for financing facility of up to EUR 11 Million
2017
17.10.2017
Agreement in principle reached on the conditions for a non-cash capital increase against a contribution in kind for the progenitor bone cell bank from Inno 4 Cell AG
22.08.2017
Annual General Meeting resolves cash capital increase with preemptive rights at a subscription ratio of 4:1
22.08.2017
Elanix Biotechnologies AG starts due diligence to acquire a fetal progenitor bone cell line within a capital increase by way of contribution in kind
29.06.2017
Elanix Biotechnologies AG: Torsten Cejka, Chairman of the Supervisory Board resigns effective on the date of next General Meeting
13.07.2017
The Management and Supervisory Board will propose to the annual general meeting a capital increase against cash contributions up to 50% granting indirect subscription rights
30.01.2017
Elanix Biotechnologies AG initiates a cash capital increase from authorized capital of up to 1,133,200 new shares with indirect shareholder subscription rights
15.04.2017
Elanix Biotechnologies AG: Restatement gem. IAS 8 im Rahmen des Konzernabschlusses 2016 geplant/Vorläufige, ungeprüfte Konzernzahlen zum Geschäftsjahr 2016 und Ausblick
24.02.2017
Elanix Biotechnologies AG: capital increase successfully placed, gross issuing proceeds amount to some EUR 4.76 million
13.01.2017
Elanix Biotechnologies AG: CEO informs about planned cash capital increase with indirect subscription rights
2016
20.06.2016
Elanix Biotechnologies AG: Vorstand Armin Schulz abberufen
11.08.2016
Elanix Biotechnologies AG: Kapitalerhöhung vollständig platziert
15.04.2016
Elanix Biotechnologies AG beschließt Kapitalerhöhung
29.07.2016
Elanix Biotechnologies AG beschließt Kapitalerhöhung gegen Bareinlagen aus genehmigtem Kapital
30.09.2016
ELANIX BIOTECHNOLOGIES AG subsidiary acquires 100% of equity of Repair-A SA
15.02.2016
Tomas Svoboda joins Management Board
04.01.2016
Reappointment of Supervisory Board
2015
24.09.2015
Porta Systems AG: Hauptversammlung schafft Voraussetzungen für Neuausrichtung als Biotechnologieunternehmen
09.12.2015
Restructuring to Biotech Company
2014
17.04.2014
Porta Systems AG wird zur ELANIX Biotech AG